Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Meir Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01270399
First received: January 4, 2011
Last updated: October 29, 2012
Last verified: March 2012

January 4, 2011
October 29, 2012
January 2011
January 2013   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01270399 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer
Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer

Lung cancer remains the most common cause of cancer-related death in the world. The major advances in treatment of lung cancer have brought only minor improvements in survival therefore novel systemic treatment methods are urgently needed.

Protein levels are regulated by the protein homeostasis network that generates and protects the protein fold (ER and Golgi included).

The heat shock protein 90 (Hsp90) is an essential molecular chaperon involved in the posttranslational folding and stability of proteins. Hsp90 inhibition leads to accumulation of unfolded proteins and ER stress. The therapeutic efficacy of such inhibition may be augmented by co-administering it with other drugs that disrupt ER-Golgi homeostasis like histone deacetylase (HDAC) or proteasome inhibitors. ER-Golgi homeostasis disruption affects a wide network of proteins and pathways as such affords a systemic target. Thus, the investigators aimed to examine the effect of combined treatment of Hsp90 antagonist with proteasome or HDAC inhibitors on human lung cancer cell lines and primary cells.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

lung tissue with primary malignant neoplasm

The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined.
Not Provided
  • malignant neoplasm's cells
  • natural cells
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
January 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • PATIENTS WITH PROVED DIAGNOSIS OF LUNG CARCINOMA THAT ARE CANDIDATS FOR RADICAL SURGICAL TREATMENT

Exclusion Criteria:

  • PATIENTS WITH SUSPICION FOR LUNG CARCINOMA WITHOUT PATHOLOGYCAL DIAFNOSIS BEFORE SURGERY
Both
18 Years and older
No
Israel
 
NCT01270399
MMC10160-2010CTIL
No
Meir Medical Center
Meir Medical Center
Not Provided
Not Provided
Meir Medical Center
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP